Zusammenfassung
Hintergrund
Die Weltgesundheitsorganisation erstellt einheitliche Definitionen und Klassifikationen von Tumoren der verschiedenen Organsysteme.
Fragestellung
Welche Änderungen ergeben sich aus der Fortschreibung der Klassifikation der Hirntumore von 2016?
Material und Methoden
Darstellung der Veränderungen bei Definition und Klassifikation der Hirntumoren in der aktuellen Fortschreibung der WHO, die sich insbesondere durch molekularpathologische Erkenntnisse der letzten Jahre ergeben.
Ergebnisse
Die aktuelle WHO-Klassifikation der Hirntumore basiert erstmals nicht mehr ausschließlich auf histologischen Charakteristika, sondern bezieht molekularpathologische Informationen in Diagnose und Klassifikation etlicher Hirntumore mit ein. Dieses gilt insbesondere für gliale Tumore, Medulloblastome und weitere embryonale Tumore.
Schlussfolgerung
Definition und Klassifikation der Hirntumore entwickeln sich in Richtung einer modularen Diagnostik, bei der histologische und molekularpathologische Informationen in eine Gesamtbewertung einfließen. Ziel ist es, dadurch zu einheitlicheren Diagnosegruppen hinsichtlich Prognose und Therapie zu kommen.
Abstract
Background
The World Health Organization (WHO) provides uniform definitions and a uniform nomenclature for tumors of various organs.
Objective
What changes resulted from the 2016 WHO classification of tumors of the central nervous system?
Material and methods
Changes in the definition and classification of brain tumors of the revised WHO classification are presented. Most changes evolve from the results of molecular pathology that were generated during the last decade.
Results
For the first time the WHO classification of brain tumors is not based exclusively on histology. Molecular parameters add to the definition of a number of tumor entities. Especially the chapters of gliomas, medulloblastomas and other embryonal tumors have been restructured.
Conclusion
Advances in molecular pathology require a modular diagnostics scheme that integrates histological and molecular parameters into a final diagnosis. This approach will result in more precise tumor groups with respect to prognosis and therapy.
Literatur
Alexandrescu S, Korshunov A, Lai SH et al (2015) Epithelial glioblastomas and anaplastic epitheloid pleomorphic xanthoastrocytomas – same entity or first cousins? Brain Pathol 26:215–223
Daumas-Duport C, Scheithauer B, O’Fallon J et al (1988) Grading of astrocytomas. A simple and reproducible method. Cancer 62:2152–2165
Ellison DW, Dalton J, Koczak M et al (2011) Medulloblastoma: clinicopathological correlates of SHH, WNT and non-SHH/WNT molecular subgroups. Acta Neuropathol 121:381–396
Hartmann C, Hentschel B, Wick W et al (2010) Patients with IDH1 wild type anaplastic astrocytoma exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognosis effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718
Herrlinger U, Jones DTW, Glas M et al (2016) Gliomatosis cerebri: no evidence for a separate brain tumor entity. Acta Neuropathol 131:309–319
Ida CM, Rodriguez FJ, Burger PC et al (2015) Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 25:575–586
Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumors of the central nervous system. Springer, Berlin, Heidelberg, New York
Kleihues P, Cavenee WK (2000) Pathology and genetics of tumors of the nervous system. IARC Press; International Agency for Research on Cancer, Lyon
Louis DN (2007) WHO classification of tumors of the central nervous system. IARC Press; International Agency for Research on Cancer, Lyon
Louis DN, Ohgaki H, Wiestler OD et al (2016) WHO classification and grading of tumors of the central nervous system. IARC Press; International Agency for Research on Cancer, Lyon
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization Classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Nobusawa S, Watanabe T, Kleihues P (2009) IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res 15:6002–6007
Ohgaki H, Kleihus P (2013) The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764–772
Pajtler KW, Witt H, Sill M et al (2015) Molecular classification of ependymal tumors across all CNS compartments, histopathological grades and age groups. Cancer Cell 27:728–743
Parker M, Mohankumar KM, Punchihewa C et al (2014) C11orf95-RELA fusions drive oncogenic NF-kappaB signalling in ependymoma. Nature 506:451–455
Perry A, Stafford SL, Scheithauer BW et al (1997) Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol 21:1455–1465
Rodriguez FJ, Schneiderjan MJ, Nicolaides T et al (2015) High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms. Acta Neuropathol 129(5):609–610
Rutkowski S, von Hoff K, Emser A (2010) Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 28:4961–4968
Scheithauer BW (2009) Development of the WHO classification of tumors of the central nervous system: a historical perspective. Brain Pathol 19:551–564
Taylor MD, Northcott PA, Korshunov A et al (2012) Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 123:465–472
Yan H, Parsons DW, Jin G (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
Zülch KJ, Avtsyn AP, Barnar RO et al (1979) Histological typing of tumors of the central nervous system. World Health Organization, Geneva
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
W. J. Schulz-Schaeffer gibt an, dass kein Interessenkonflikt besteht.
Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Schulz-Schaeffer, W.J. Neuerungen der WHO‑Klassifikation der Hirntumore von 2016. Radiologe 57, 701–706 (2017). https://doi.org/10.1007/s00117-017-0290-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00117-017-0290-3
Schlüsselwörter
- Definitionen
- Tumore des zentralen Nervensystems
- Molekulare Pathologie
- Modulare Diagnostik
- Gesamtbewertung